Harvard's Wyss Institute launches NuProbe to facilitate global precision medicine

(Wyss Institute for Biologically Inspired Engineering at Harvard) NuProbe Global will commercialize the Wyss Institute's DNA nanotechnology-based variant-detecting method as a fast, low-cost and multiplexed molecular diagnostic for different disease areas, including cancer and infectious diseases. The announcement follows a worldwide licensing agreement between Harvard's Office of Technology Development (OTD) and globally-operating NuProbe that will leverage the technology to develop clinical assays capable of simultaneously detecting multiple rare disease-related DNA variants in bodily fluids.
Source: EurekAlert! - Biology - Category: Biology Source Type: news